Eli Lilly and Company (VIE:LLYC)

Market Cap	760.56B +19.8%
Revenue (ttm)	55.51B +45.4%
Net Income	17.58B +120.0%
EPS	19.55 +121.0%
Shares Out	n/a
PE Ratio	43.27
Forward PE	30.00
Dividend	5.35 (0.58%)
Ex-Dividend Date	Nov 14, 2025

Volume	41
Average Volume	48
Open	858.50
Previous Close	873.90
Day's Range	845.90 - 917.30
52-Week Range	539.10 - 965.00
Beta	n/a
RSI	55.28
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: LLYC

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD